 |
|
Anthony Ross, Director, Healthcare Group
3i plc
Antony Ross became Director of 3i Cambridge in August 1997 and manages
3i’s Healthcare Team. 3i are a leading investor in Healthcare
and supporting businesses from early stage through to IPO. These
include Weston Medical, Pharmagene, Morphosys and Inpharmatica.
The Healthcare Team comprises over 25 specialist investors working
across Europe. Antony joined 3i in 1988 working in the London office
and, prior to moving to Cambridge, managed 3i's Newcastle office.
He is an Engineer and before joining 3i, he obtained an MBA at the
London Business School.
back
to top
|
 |
|
 |
|
Dr. Paul Haycock, Director
Apax Partners
Dr Paul Haycock is a Director of Apax Partners, a leading UK venture
investment company. Dr Haycock graduated in medicine from London
University and completed post-graduate studies at the University
of British Columbia. After five years clinical practice in Canada,
Dr Haycock moved into pharmaceutical and clinical research with
Roussel Uclaf and later obtained a diploma in pharmaceutical medicine
and an MBA from the Cranfield School of Management. Dr Haycock has
over twenty years experience of the pharmaceutical and biotechnology
industries in positions including the managing directorships of
Duphar Laboratories and Novo-Laboratories UK and senior medical
and management positions in Europe and the USA with NovoIndustri
A/S and Squibb-Novo Inc. Most recently Dr Haycock was Chief Executive
of Cantab Pharmaceuticals, a public biotech company quoted on NASDAQ
and the LSE. Dr Haycock has been Chairman of the BioIndustry Association
and is a Fellow of the Faculty of Pharmaceutical Medicine of the
Royal College of Physicians.
back
to top
|
 |
|
|
|
Joël Besse, Senior Principal, Life
Sciences
Atlas
Venture
Joël Besse joined Atlas Venture in 1995. After serving as an
auditor at Arthur Andersen and at Crédit Lyonnais in Paris,
he began his career in venture capital in 1991 with SED Ventures,
a firm specializing in international life sciences investments.
Joël holds a Master of Science degree from
the University of Toulouse and graduated from Ecole Nationale Supérieure
de I'Aéronautique et de l'Espace.
Board participation includes:
Actelion Pharmaceuticals Ltd, EntoMed SA, Immuno-Designed Molecules
SA, Modex Therapeutiques SA, Neurotech SA, Novuspharma Invest NV.
back
to top
|
 |
|
|
|
Prof. Jesper Zeuthen, Managing Director
BankInvest
Bio Venture
Jesper Zeuthen has been working for the BankInvest Group as a consultant
since 1988, and he decided to join us full time in spring 2000 working
primarily with venture capital. Previously, Jesper Zeuthen has worked
as Head of R & D at Novo Nordisk and Head of Research at The
Danish Cancer Society. He is the author of more than 200 publications
in immunology, cell biology and molecular biology and served as
adjunct professor of biotechnology at the University of Copenhagen.
back
to top
|
 |
|
|
|
Andy Gearing, CEO
Biocomm
International
Dr Andy Gearing arrived in Australia to establish Biocom Services
in January 2001 having previously worked in the European biotechnology
industry. Dr Gearing has a successful track record in research management
in both government and commercial biotechnology organisations. He
has managed research and development projects in cytokine biology,
immunology, inflammation and neurobiology. He has published over
90 papers, books and patents and organised several international
conferences in these areas. Prior to moving to Biocomm, Dr Gearing
was responsible for identifying and in-licensing projects into British
Biotech’s portfolio, as well as leading teams involved in the
out-licensing of British Biotech’s Metalloenzyme technology.
back
to top
|
|
|
|
|
Otello Stampacchia
Biotech
Private Equity Advisors
Born in Italy in 1969, Otello studied genetics in the University
of Pavia, Italy, from 1987 till his Master in Genetics in 1991,
Magna cum Laude, with a research thesis on plant genetic engineering.
He continued his studies till obtaining a Ph.D. in Molecular Biology
from the University of Geneva in 1997. During his academic studies,
Otello also developed an interest for Biotechnology Patent Law,
with internships at Bird & Bird (London). His academic curriculum
was completed by his Ph.D. in Biotechnology granted by the European
Union in 1998.
During 1997-1998, Otello worked for Index Securities,
Geneva, a merchant banking/venture capital firm, directing their
biotechnology practice. Otello then moved to Goldman Sachs in London,
where he worked in the Corporate Finance/Mergers and Acquisition
practice for health care and biotechnology US and European clients.
Otello joined Lombard Odier in January 2001 as
Manager for the Lombard Odier Immunology Fund, focusing on small
cap and private biotechnology investments. He left Lombard in December
2001 and is now acting as advisor to several Institutional investors
and private companies.
back
to top
|
 |
|
|
|
Dr. Kai-Uwe Bindseil, CEO
BioTop
Dr. Kai-Uwe Bindseil studied chemistry at Georg August University
in Göttingen. In 1993, he wrote his doctoral thesis in bioorganic
chemistry under the guidance of Prof. A. Zeeck. After a post-doctoral
fellowship at Ciba-Geigy AG in Basle, he moved to AnalytiCon in
1994, where he is currently responsible for drug discovery, marketing
and business development. As of mid-August he has become CEO of
BioTOP.
back
to top
|
 |
|
|
|
Dr David Chiswell BSc PhD, Founder and
Former CEO
Cambridge Antibody Technology
David Chiswell was been responsible for the operational management
of CAT from its inception. He joined the Board in December 1995
and took the role of Chief Executive Officer in 1996.
Prior to CAT he spent nine years at Amersham International
plc where his main responsibilties included product development
and research management. David’s research experience was gained
at the Medical Research Council (MRC) Institute of Virology in Glasgow,
the Department of Immunology and Microbiology at UCLA, California
and the Department of Tumour Virology at the Imperial Cancer Research
Fund in London.
back
to top
|
 |
|
|
|
Dr. Eric Tambuyzer, Chairman EuropaBio
Board of Management,
Vice Preseident, Corporate Affairs Europe
GENZYME
Corporation
Dr. Tambuyzer is Genzyme Corporation’s Vice President Corporate
Affairs Europe, and a member of the European Executive Board of
Genzyme.
Starting his professional career at Baxter Health Care in 1977,
he pursued his career six years later at Innovi NV (Brussels, Belgium).
In 1985 he co-founded the biotech company Innogenetics NV (Ghent,
Belgium), of which he was general manager until 1992, when he joined
Genzyme as Vice President Diagnostics and Genetics Europe.
In October 2000, Dr. Tambuyzer was elected Chairman
of the Board of EuropaBio, the European Association for Bioindustries,
of which he is also founder & Chairman of the Ethics Working
Group. Dr. Tambuyzer is a Board Member of the European Platform
for Patients’ Organizations, Science & Industry, EPPOSI,
and of EBE, the Emerging Biopharmaceuticals Enterprises group, a
specialised group within EFPIA, the European Pharmaceutical industry
organisation. He is also a Member of the Board of Directors of the
BBA (Belgian Bioindustries Association). He is an adviser to international
journals and Chairman of the Advisory Board of the Life Sciences
Fund of Dresdner Kleinwort Capital.
Dr. Tambuyzer is a bio-engineer and holds a doctoral
degree in bio-industrial sciences from the University of Leuven,
(KUL), Belgium. A Belgian citizen, born in 1949, he is married and
has 3 children.
back
to top
|
 |
|
|
|
Berthold Hackl, Managing Partner
Heidelberg
Innovation
Berthold Hackl, Managing Partner, Heidelberg Innovation; molecular
biologist, MBA INSEAD. After receiving his diploma, he started as
product specialist with a leading biotech systems provider where
he advanced to General Manager Europe (Pharmacia Biosensor, now
Biacore) and was responsible for the market introduction of a novel
biosensor technology. He later gained extensive experience in building
and managing health care businesses, among others in the executive
management of Stratec Medical (now Synthes-Stratec). His experience
also includes holding management and turnaround situations, and
the management of the successful public offering (Neuer Markt) of
the French biotech company Eurofins Scientific.
back
to top
|
 |
|
|
|
Susan Searle, Managing Director
Imperial
College Innovations
Susan Searle is an Oxford educated Chemist. She started her career
working for Shell Chemicals and moved to Shell International working
as a business and product development manager covering plastics,
resins and base chemicals. After 3 years she moved to the Bank Of
Nova Scotia where she was appointed marketing manager for gold bullion
products where she developed a European client base and secured
backing for a new business; gold leasing.
Susan then entered the technology transfer business
and spent a year in Australia developing and licensing technologies
from the science and engineering faculty at Monash University. She
established a network of investors and launched a technology precinct
which brought some 700 local companies together.
On her return for the UK she spent several months
consulting for Imperial who were not at that stage ready to invest
seriously in technology transfer. She joined the Signet group, a
retail organisation and held a variety of roles which involved troubleshooting
and re-organising parts of the business and acting as an internal
consultant. She established an import operation in Italy re-sourcing
product direct to supplier and traded gold for the company. She
ran a buying team managing stock control, range selection and merchandising.
However, bored of retail products, Susan saw the
opportunity to join IMPEL, Imperial’s technology transfer company,
in 1994. The team at the time was small, she joined as a senior
executive managing science and engineering technologies. IMPEL has
now evolved into Imperial College Innovations Ltd and grown to a
staff of 23. It has some 53 spin out companies which have been established
based on Imperial’s research and some 40 more in the pipeline.
IC Innovations has a “hands on” approach to establishing
new companies. Susan has been instigative in the development and
growth of the organisation including involvement in a number of
successful government bids for seed funds and exploitation/incubation
platforms.
Susan became Commercial Director of IC Innovations
in 1999 and was appointed Managing Director in January 2002.
She currently holds directorships on a number
of boards; Casect (gas detection systems), Powerlase (laser systems),
Adapative Screening (drug discovery), Nanobiodesign (diagnostics),
Holoscan (ultrafast imaging). She was on the board of Turbogenset,
Imperial’s leading success which floated in 2000 and realised
£10.2m in return for 25% of Imperial’s holding.
back
to top
|
|
|
|
|
Dr. Tim Cook, Managing Director,
Isis Innovation
After being awarded a doctorate in cryogenic engineering at Oxford,
Tim Cook joined the Oxford Instruments Group in 1975. During his
12 years with them, the group’s turnover grew from £1m
to £100m. In 1983 Tim was appointed Managing Director of their
subsidiary Oxford Analytical Instruments.
After two more Managing Director appointments,
Tim set up as a private investor in 1990 and was founding Managing
Director of Oxford Semiconductor and Oxford Asymmetry, a spinout
from the University of Oxford which was floated in 1998 and was
recently sold for over £340 million.
In 1997, Tim Cook was appointed Managing Director
of Isis Innovation, the University of Oxford’s technology transfer
company. Since then, Isis has recruited 23 staff and negotiated
over 75 option and licence agreements. In the last three years,
Isis has established 24 new spin-out companies from the University
with a current estimated value of £200 million.
back
to top
|
 |
|
|
|
Philip Rattle, Partner
JPMorgan Partners
Philip Rattle has worked in the Venture Capital
industry since 1989. Prior to joining JPMP in 1998 he was with 3i
plc in London where he invested in Morphosys, Shire, Alliance Medical
and Antisoma, amongst others. He is responsible for JPMP's Life
Science and Healthcare MBO investments in Europe and sits on the
boards of Renovo, Ribotargets, Microscience and Lorantis. He holds
a BA (Hons) from Oxford University.
back
to top
|
|
|
|
|
Yalin Karadogan, Investment Manager
JPMorgan Partners
Mr. Karadogan works in JPMorgan Partners' London
office, where he focuses on European Life Sciences & Healthcare.
His recent work includes the team's investments in Renovo, Lorantis,
RiboTargets, and Microscience. Prior to his move to London in 2000,
Mr. Karadogan was with JPMorgan Partners' Life Sciences & Healthcare
Infrastructure team in New York, where he worked on the Coulter,
Endeavor and Medsite investments. Mr. Karadogan first joined JPMorgan
Partners in early 1998 and initially worked in the Octagon Investment
Partners team in New York, focusing on high yield bond and leveraged
loan investments in the healthcare sector. Previously, Mr. Karadogan
worked in Chase Manhattan Bank's Global Trade Finance & Advisory
group. Mr. Karadogan holds a B.A. in Mathematics & Economics,
Summa Cum Laude and Phi Beta Kappa, from Lafayette College in the
USA.
back
to top
|
 |
|
|
|
Stan Yakatan, Chairman
Katan Associates
After 30 years as a successful CEO, entrepreneur,and operational
manager, Stan Yakatan has dedicated the last 7 years of his career
to sharing his experiences with management teams interested in building
technology based companies. His experience as an executive and in
several instances serving as CEO with New England Nuclear, EI Dupont,
ICN Pharma, New Brunswick Scientific and Biosearch, provided him
with management and corporate finance acumen that he enjoys sharing
with others. He has founded or co-founded in excess of 15 companies
in the United States, Canada, Israel, France and Germany and in
many cases served as the initial CEO, and Chairman of these companies.
He currently sits on the board of directors of several public and
private companies and has advised several of the world's leading
venture capital firms including TVM (Germany), Ventana (USA), MSP
(USA) and Biocapital (Canada). He has completed and advised on numerous
acquisitions and corporate finance transactions raising in excess
of $1.0 billion dollars in the public and private capital financing
markets. He is a frequent speaker at financial and biotechnology
conferences throughout the world speaking on topics including, "Capital
Raising for the Technology-Based Start-Up" and "The Need
to be Global in the Quest for Capital and Partners". Rick Biondi,
Editor of Lab Business Magazine stated," Mr Yakatan is a venture
capital raising Guru and it is part of his genetic make up."
He currently serves as the strategic advisor to the state government
of Victoria, Australia and is the Chairman of Katan Associates International
with headquarters in New York City.
back
to top
|
 |
|
|
|
Rachel Maguire, Head of UK Issuer Services
London Stock
Exchange
Rachel Maguire is Head of UK Issuer Services and Head of AIM UK.
She has worked for the London Stock Exchange for around 4 years,
having originally joined as the Regional Manager for the Midlands
in 1998 .
Rachel graduated with a combined honours degree
in English and German from the University of Birmingham and is a
member of the Chartered Institute of Taxation. Post graduation,
she specialised in heavy-duty personal tax planning at the then
Coopers & Lybrand and latterly, Deloitte & Touche. The main
focus of her work was financial and investment management through
to company-focused issues such as remuneration planning (including
share schemes) and exit strategies.
back
to top
|
 |
|
|
|
Anthony Warnock-Smith, Partner
Morgan
Lewis
Anthony Warnock-Smith, a partner in the London office of Morgan
Lewis and the European head of the Life Sciences Practice, focuses
on the pharmaceutical, medical device, cosmetics, veterinary drug,
and foods and food additives industries.
Mr. Warnock-Smith has 25 years of experience in
regulatory matters, as well as commercial agreements and transactions.
His regulatory experience involves the full range of issues, from
clinical trial and product development issues, to marketing and
allied reimbursement, product liability and other trade regulation
matters. He is also experienced in corporate and commercial transactions,
European Union competition law, and strategic partnering.
From 1973 until 1996, Mr. Warnock-Smith worked
at Sterling Winthrop (now Sanofi-Synthelabo), rising to vice president
of legal services in Europe.
back
to top
|
 |
|
|
|
Dr. Michael Dalrymple, Director
MRC Technology
A PhD molecular biologist and MBA, Michael Dalrymple joined the
MRC in 1998 as Director of the MRC Collaborative Centre Scotland
having spent eight years at PPL Therapeutics, latterly as head of
their ‘product discovery’ function responsible for in-licensing.
Re-organisation of MRC technology transfer activities in 2000 saw
the formation of a new technology transfer company, Medical Research
Council Technology (MRCT), and Michael became Director of the ‘Applied
Research’ Division (ARD) of MRCT which has laboratories in
Edinburgh and Mill Hill, north London. As Director of ARD, he is
responsible for running the two in-house research centres as well
as assisting colleagues in developing commercialisation opportunities
more widely.
back
to top
|
 |
|
|
|
David Gandy, Senior Managing Director
NASDAQ
Europe
David Gandy joined Nasdaq Europe in January 2002 as Senior Managing
Director. Prior to Nasdaq he spent 14 years at Reuters Plc. He held
executive positions including Global Managing Director of Reuters
Information Ltd, responsible for the company’s Equities and
Fixed Income business. Prior to that he was Global Managing Director
of Strategic and Commercial business, Managing Director of the European
Division, and Deputy Managing Director, UK.
Prior to Reuters he held senior positions at SKF in Sweden and executive
positions within the Shell/Billiton Group.
He has lived and worked in Sweden, Holland, France,
Germany, Japan and Scotland. He holds a BSc in Mechanical Engineering
from Birmingham University and an HND in Business and Finance from
Glasgow University.
back
to top
|
 |
|
|
|
Dr Juerg Meier, Executive Director
Novartis
Venture Fund
Since 1998 Juerg MEIER has been the Executive Director of the Novartis
Venture Fund. This life science venture fund helped with CHF 100
Mio plus USD 100 Mio the start-up and spin-off of many companies
worldwide. Its portfolio includes at present 110 companies at various
stages of development and financing (see www.venturefund.novartis.com).
Previously, he was working over 25 years in various international
functions of the former company SANDOZ Pharma Ltd.: Head R+D of
BIOCHEMIE Ges.m.b.H. in Austria, Head of R+D in the US, Head of
R+D Sandoz Pharma worldwide, President of Sandoz Pharma Japan. As
a member of the Swiss National Science Foundation Jürg Meier
supervises three of the 14 new NCCR programs (National Centers of
Competence in Research). He is further involved in the Center for
Technology Assessment at the Swiss Science and Technology Council
and in the Swiss Network for Innovation.
back
to top
|
 |
|
|
|
Dr. Ismail Kola, Vice President, Discovery
Research and Global Head: Genomic Sciences and Pharamcogenomics
Pharmacia
Corporation, U.S.A.
Ismail Kola was born in 1957 and graduated B.Sc. (University of
South Africa); B.Pharm cum laude (Rhodes); and Ph.D. (Med) (Cape
Town).
He has authored over 125 publications, many in
the most eminent scientific journals and is a named inventor on
twelve patents. He is the recipient of several international research
prizes.
He was previously: Professor of Human Molecular
Genetics, Monash Medical School; Director of the Center for Functional
Genomics, Monash; and Member of the International Genomics Advisory
Board for SmithKline Beecham Pharmaceuticals.
He is currently Vice-President of Research, and
Global Head of Genomics for Pharmacia (8th largest global pharmaceutical
company with a market capitalization of US$55 billion). He is also
a member of: the Research and Leadership Team of Pharmacia, Pharmacia-Washington
University Advisory Board, Pharmacia-M.D.Anderson Advisory Board;
Chairman of the Joint Steering Committee of the Pharmacia- Karolinska
Institute Collaboration, and Co-chair, Pharmacogenomics Operations
Team, Pharmacia. He is Adjunct Professor of Medicine at Washington
University (St Louis) and Monash, and on the Board of Directors
of Eragen Biosciences.
back
to top
|
 |
|
|
|
Brian Chee, General Partner
Polaris
Venture Partners
Brian Chee is a general partner in our Seattle office. He joined
Polaris in August 1996. Brian focuses on investment opportunities
in medical and information technology.
Experience: Prior to becoming a technology
investor, Brian gained significant experience in business operations
and leadership.
Brian is a decorated veteran, having served as Captain in the US
Army Corps of Engineers. His service included command of 42 combat
engineer soldiers during the Gulf War. As platoon leader, Brian
was awarded the Bronze Star and the Army Commendation Medal with
Valor for successfully completing missions while encountering enemy
fire on the front lines. He also worked at Baxter International,
a world leader delivering medical products and solutions to healthcare
professionals.
Boards: Brian represents Polaris on the
boards of directors of Circe Biomedical, DSI, eSurg, MedVantx, Noetix,
Optobionics, and Sentillion.
Education: Brian holds an MBA from the
Amos Tuck School of Business at Dartmouth College and a BS in engineering
and economics from the United States Military Academy at West Point
where he made dean's list all four years.
back
to top
|
 |
|
|
|
Dr. Andrew Clark, Director
Reabourne
Technology Investment Management Limited
Dr. Andrew Clark jointly founded Reabourne in 1995. He was formerly
a Biotechnology and Pharmaceutical Analyst with Barings Securities
Limited and a Quantative Research Analyst with Smith Newcourt Securities.
Prior to entering the finance industry, Dr. Clark was a post-doctoral
research fellow at Oxford University after receiving a PhD from
St. Andrew’s University.
back
to top
|
 |
|
|
|
Prof. Graham Boulnois, Venture Partner
Schroder
Ventures Life Sciences
Professor Graham Boulnois joined SVLS as a full-time Venture Partner.
Before joining SVLS, Graham was senior vice president of Drug Innovation
and Approval at Aventis Pharma AG. At Aventis he had global responsibility
for lead generation covering Functional Genomics, screening, medical
and synthetic chemistry, chemical development and informatics, in
addition to R&D portfolio management as part of the senior R&D
team. Prior to joining Aventis, Graham spent a number of years at
AstraZeneca Pharmaceuticals, latterly as global Vice President and
Head of Enabling Science and Technology.
Graham has a BSc in biological science and a PhD
in molecular biology from the University of Leicester.
back
to top
|
 |
|
|
|
Dr. Silvano Fumero, Senior Executive Vice-President,
Head of Research and Pharmaceutical Development
Serono
International S.A.
Dr Silvano Fumero is Senior Executive Vice President, Head of Research
& Pharmaceutical Development at the Serono Group in Geneva,
since April 1996. Dr Fumero's career started in the 1970's, when
he filled a succession of research positions in the fields of biochemistry,
steroid receptors, mutagenesis and toxicology. After two years in
Brussels at the EEC as toxicologist (DG III Chemical Industry),
Dr Fumero was appointed General Manager in 1987 of Istituto di Ricerche
Biomediche A. Marxer (RBM) in Ivrea, the first Italian contract
research organisation. He became Vice President of LCG Bioscience
in London, a division of Serono which is a network of CRO's offering
R&D services to pharmaceutical and biotechnology companies.
He is also contract professor in "Organisation and Planning
of R&D", at the University of Turin (Faculty of Science,
Biotechnology).
back
to top
|
 |
|
|
|
Frances Bornstein, Deputy Head SWX New
Market
SWX
Swiss Exchange
Frances Bornstein holds a degree in business management from Ludwig-Maximilians
University in Munich. Following her studies, she was initially a
consultant to the retailing industry. In 1996, she turned to business
journalism, working as a television reporter and for an agency specialised
in financial market news. She has held the post of Deputy Head of
Key Account Issuers and Deputy Head of SWX New Market with the SWX
Swiss Exchange since 1998.
back
to top
|
 |
|
|
|
Prof. Roger Ekins MA, PhD, Dsc, FRS,
Head of Department, Molecular Endocrinology
UCL Medical School,
UCL
Professor Ekins is internationally recognised as the independent
co-originator (with Drs Berson and Yalow) of radioimmunoassay (RIA)
and related microanalytical techniques. Widely used to assay hormones
and many other biologically-important substances in medical research
and diagnosis, introduction of these techniques made a revolutionary
impact on medicine, creating the $10 billion immunodiagnostics industry.
In the mid-1980s he conceived of and patented
a new generation of ultrasensitive, miniaturised, assays for protein
and DNA/RNA measurement based on the use of “microarrays”,
this leading, in 1991, to his collaboration with Boehringer Mannheim
in the technology’s further development. Though outstandingly
successful, the “Microspot®” project was (for legal
reasons unrelated to the project’s success or the technology’s
commercial prospects) halted in 1998 by Hoffmann-la Roche following
its purchase of BM. Meanwhile international interest in microarray
technology has exploded, being predicted by US analysts to form
the basis of a $40 billion industry within the next decade.
Professor Ekins has received many premier awards
in recognition of his work in clinical chemistry, nuclear medicine,
and endocrinology, including the IFCC’s Distinguished Clinical
Chemist Award, the von Hevesy Foundation’s Georg von Hevesy
Gold Medal, the British Nuclear Medicine Society’s Veall medal,
the Society for Endocrinology’s Dale Medal, and, most recently,
the AACC’s inaugural Edwin F Ullman Award.
back
to top
|
 |
|
|
|
Prof. Stephen K. Smith, Head of Department,
Obstetrics & Gynaecology
University of Cambridge
Professor Stephen Smith was appointed Head of the Department of
Obstetrics and Gynaecology at the University of Cambridge in 1988
and he is Head of Service for Women’s Health at Addenbrooke’s
Hospital. Professor Smith is a Fellow of the Academy of Medical
Sciences, a Fellow of the Royal College of Obstetricians and Gynaecologists,
a Fellow of the Institute of Biology and a member of many learned
societies and editorial board member of numerous international scientific
journals. Professor Smith is a leading expert on the subject of
angiogenesis in the female reproductive tract and is currently studying
the way in which multiple gene expressions regulate vascular structure
in the endometrium.
back
to top
|
 |
|
| |
| |